Clinical trial NCT04027803: Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris®
Official title: A Double-blind, Randomized Clinical Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 (JSC BIOCAD, Russia) and Soliris® in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Subjects
Lead sponsor: Biocad
Sponsor class: INDUSTRY
First posted: 2019-07-22
Enrollment: 78
Sex: MALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A Double-blind, Randomized Clinical Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 (JSC BIOCAD, Russia) and Soliris® in Healthy Volunteers


Eligibility criteria: Inclusion Criteria:

1. Signed ICF for participation in the study
2. Men from 18 to 45 years old (inclusive) at the time of signing the ICF
3. BMI within the normal limits (18.0 to 30 kg/m2)
4. The subject is able to follow the Protocol procedures (in the investigator's opinion)
5. The subject is verified as "Healthy" according to results of standard clinical, laboratory and instrumental tests
6. Normal hemodynamic parameters: systolic BP from 90 mmHg to 130 mmHg; diastolic BP from 60 mmHg to 90 mmHg; HR from 60 bpm to 90 bpm
7. The subject and his sex partner of childbearing potential consent to implement reliable contraceptive methods from the moment the subject signs the ICF and until the subject completes the study. This requirement does not apply to those subjects who had undergone surgical sterilization. Reliable contraception methods mean one barrier method in combination with one of the following: spermicides, intrauterine device and/or oral contraceptives used by the subject's partner.
8. The subject agrees not to drink alcohol for 24 h prior to the infusion of the test/reference drug and for the entire period while the subject is in the study.

   -

Exclusion Criteria:

1. Psychiatric disorders or other conditions that can affect the ability of the subject to follow the study protocol
2. Acute infections within 4 weeks before signing the ICF
3. Results of laboratory and/or instrumental tests are outside the site's normal range
4. Any surgery done within 30 days before the screening or planned within 30 days after the subject completes the study
5. Impossibility to insert an intravenous catheter for blood collection (e.g., because of a skin condition at the venipuncture site)
6. A history of allergies
7. Known hypersensitivity to any component of BCD-148 or Soliris®, murine proteins or other drug components; hypersensitivity to any component of the meningococcal vaccine
8. The subject had used any medications that significantly affect hemodynamics, liver function, etc. (barbiturates, omeprazole, cimetidine, etc.) within 30 days before signing the ICF and/or the subject needs any medications (other than the study drugs) to be taken during the entire study period
9. The subject had previously used eculizumab and/or other therapeutic monoclonal antibodies against complement C5
10. Regular use (oral or parenteral) of any drugs, including OTC products, vitamins or biologically active supplements within 14 calendar days before signing the ICF
11. A history of recurrent/chronic hemorrhages or any hemorrhage within 30 days prior to signing the ICF
12. Acute or chronic infections or other diseases that, in the investigator's opinion, may affect the PK, PD or safety of the study products
13. HIV, HCV, HBV infection, syphilis.
14. Meningococcal infection in the past (documented or mentioned verbally by the subject)
15. Vaccination within 4 weeks before the planned infusion date, except for vaccination against Neisseria meningitidis given to all subjects in the screening period
16. The subject refuses to get a vaccination against Neisseria meningitidis during the screening period .
17. The subject smokes more than 10 cigarettes per day
18. The subject consumes more than 10 units of alcohol per week (1 unit equals to 0.5 L of beer, 200 mL of wine or 50 mL of a strong alcohol beverage) or has a history of alcohol, recreational drug or medication abuse, or tests positive for alcohol and/or psychoactive substances during the screening examination
19. Donation of ≥ 450 mL of blood or plasma within 60 calendar days before signing the ICF.
20. Participation in any drug clinical studies within 30 calendar days prior to signing the informed consent form and through the entire period of study participation.

    -

Primary outcomes:
measure: AUC0-∞ of Eculizumab
timeFrame: from 0 to 1392 hours post-infusion
Secondary outcomes:
measure: Cmax of Eculizumab
timeFrame: from 0 to 1392 hours post-infusion
measure: Тmax of Eculizumab
timeFrame: from 0 to 1392 hours post-infusion
measure: AUC0-1392 of Eculizumab
timeFrame: from 0 to 1392 hours post-infusion
measure: Т1/2 of Eculizumab
timeFrame: from 0 to 1392 hours post-infusion
measure: Vd of Eculizumab
timeFrame: from 0 to 1392 hours post-infusion
measure: Кel of Eculizumab
timeFrame: from 0 to 1392 hours post-infusion
measure: Cl of Eculizumab
timeFrame: from 0 to 1392 hours post-infusion
measure: ABEC(0-1392) CH50
timeFrame: from 0 to 1392 hours post-infusion
measure: AUEC(0-1392) CH50
timeFrame: from 0 to 1392 hours post-infusion
measure: Emin CH50
timeFrame: from 0 to 1392 hours post-infusion
measure: Tmin CH50
timeFrame: from 0 to 1392 hours post-infusion
measure: Subjects With AEs/SAEs Related to Eculizumab
timeFrame: from 0 to 1392 hours post-infusion
measure: Subjects Who Develop Grade 3/4 AEs Related to Eculizumab
timeFrame: from 0 to 1392 hours post-infusion
Other outcomes:
Locations:
city: Saint Petersburg
country: Russian Federation
facility: Limited Liability Company Research Center Eco-Bezopasnost (OOO Research Center Eco-Bezopasnost)
Study officials:
References: